Your search history is turned on.
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Clearmind Applies to Cease Being a Reporting Issuer in Canada Vancouver, Canada, April 30, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWYO) ("Clearmind" or the Company), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it will apply to th...
Date: March 18, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - CMND - CFO Certificate q1 2024 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Alan Rootenberg, Chief Financial Officer of Clearmind Medicine Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Clearmind Medicine Inc. (the iss...
Microsoft Word - CMND - CEO Certificate q1 2024 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Clearmind Medicine Inc. (the is...
file:///N:/EDGAR%20FILES/1-PreSub/ea0200890/ea0200890-01/ea0200 Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENTS DISCUSSION AND ANALYSIS For the Three Months Ended January 31, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Managements Discussion and Analysis For the Three Months Ended January 31, 2024 This ...
file:///N:/EDGAR%20FILES/1-PreSub/ea0200890/ea0200890-01/temp_v Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended January 31, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed ...
Date: March 13, 2024 Jurisdictions: Alberta, British Columbia, Ontario
FORM 51-102F3 MATERIAL CHANGE REPORT ITEM 1 Name and Address of Company Clearmind Medicine Inc. (the Company) 101 1220 West 6th Avenue Vancouver, British Columbia ITEM 2 Date of Material Change March 13, 2024. ITEM 3 News Release A news release was disseminated on March 13, 2024 through the facilities of Accesswire and subs...
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeut...
Date: February 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds New patent applications build upon Clearminds broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (Clearmind or the company), ...
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (Clearmind or the "company"), a biotech company focu...
Date: February 20, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to...